Log in

OTCMKTS:STXS - Stereotaxis Stock Price, Forecast & News

0.00 (0.00 %)
(As of 02/17/2020 07:28 AM ET)
Today's Range
Now: $4.25
50-Day Range
MA: $4.89
52-Week Range
Now: $4.25
Volume124,030 shs
Average Volume259,443 shs
Market Capitalization$283.56 million
P/E RatioN/A
Dividend YieldN/A
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolOTCMKTS:STXS
Previous SymbolNASDAQ:STXS



Sales & Book Value

Annual Sales$29.35 million
Cash Flow$0.02 per share
Book Value($0.02) per share


Net Income$120,000.00


Market Cap$283.56 million
Next Earnings Date3/10/2020 (Estimated)
OptionableNot Optionable

Receive STXS News and Ratings via Email

Sign-up to receive the latest news and ratings for STXS and its competitors with MarketBeat's FREE daily newsletter.

Stereotaxis (OTCMKTS:STXS) Frequently Asked Questions

What is Stereotaxis' stock symbol?

Stereotaxis trades on the OTCMKTS under the ticker symbol "STXS."

How were Stereotaxis' earnings last quarter?

Stereotaxis Inc (OTCMKTS:STXS) released its quarterly earnings data on Thursday, August, 8th. The medical equipment provider reported ($0.03) EPS for the quarter. The medical equipment provider earned $6.80 million during the quarter. Stereotaxis had a negative return on equity of 1,456.01% and a negative net margin of 14.80%. View Stereotaxis' Earnings History.

When is Stereotaxis' next earnings date?

Stereotaxis is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Stereotaxis.

Has Stereotaxis been receiving favorable news coverage?

Media coverage about STXS stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Stereotaxis earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Stereotaxis.

Who are some of Stereotaxis' key competitors?

What other stocks do shareholders of Stereotaxis own?

Who are Stereotaxis' key executives?

Stereotaxis' management team includes the folowing people:
  • Mr. David Leo Fischel C.F.A., CFA, CPA, CEO & Chairman (Age 32)
  • Mr. Martin C. Stammer, Chief Financial Officer (Age 39)
  • Mr. Kevin M. Barry, Chief Legal Officer, Corp. Sec. & Chief Compliance Officer
  • Dr. Gery Tomassoni M.D., FHRS, Chief Medical Officer
  • Dr. J. David Burkhardt, Chief Devel. Advisor

Who are Stereotaxis' major shareholders?

Stereotaxis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Parkman Healthcare Partners LLC (0.80%), Essex Investment Management Co. LLC (0.38%), EAM Investors LLC (0.29%), Renaissance Technologies LLC (0.18%), Independent Advisor Alliance (0.06%) and Oxford Asset Management LLP (0.05%). View Institutional Ownership Trends for Stereotaxis.

Which institutional investors are buying Stereotaxis stock?

STXS stock was acquired by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, Essex Investment Management Co. LLC, EAM Investors LLC, Renaissance Technologies LLC, Oxford Asset Management LLP, Virtu Financial LLC, Goldman Sachs Group Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for Stereotaxis.

How do I buy shares of Stereotaxis?

Shares of STXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Stereotaxis' stock price today?

One share of STXS stock can currently be purchased for approximately $4.25.

How big of a company is Stereotaxis?

Stereotaxis has a market capitalization of $283.56 million and generates $29.35 million in revenue each year. Stereotaxis employs 119 workers across the globe.View Additional Information About Stereotaxis.

What is Stereotaxis' official website?

The official website for Stereotaxis is http://www.stereotaxis.com/.

How can I contact Stereotaxis?

Stereotaxis' mailing address is 4320 FOREST PARK AVENUE SUITE 100, ST.LOUIS MO, 63108. The medical equipment provider can be reached via phone at 314-678-6100 or via email at [email protected]

MarketBeat Community Rating for Stereotaxis (OTCMKTS STXS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  117 (Thanks for Voting!)
Underperform Votes:  128 (Thanks for Voting!)
Total Votes:  245
MarketBeat's community ratings are surveys of what our community members think about Stereotaxis and other stocks. Vote "Outperform" if you believe STXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: What is a Derivative?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel